measureId,stratumName,description
AAD14,examPerformed,NUMERATOR CRITERIA 1: Documentation by the provider who performed the surgery that an exam for recurrence of melanoma was performed on the patient within the reporting period.
AAD14,overall,NUMERATOR CRITERIA 2: All patients that were diagnosed with a recurrent melanoma in the current reporting year.
AAD16,resection,Strata 1: Intermediate layer or complex linear closures after skin cancer resection
AAD16,reconstruction,Strata 2: Reconstruction after skin cancer resection
AAD16,overall,"Strata 3: Strata 1 + Strata 2; Calculate as (numerator 1 + numerator 2 )/(denominator 1 + denominator 2), not the average of the performance rates"
AAD17,resection,Strata 1: Intermediate layer or complex linear closures after skin cancer resection
AAD17,reconstruction,Strata 2: Reconstruction after skin cancer resection
AAD17,overall,"Strata 3: Strata 1 + Strata 2; Calculate as (numerator 1 + numerator 2 )/(denominator 1 + denominator 2), not the average of the performance rates"
AAD18,resection,Strata 1: Intermediate layer or complex linear closures after skin cancer resection
AAD18,reconstruction,Strata 2: Reconstruction after skin cancer resection
AAD18,overall,"Strata 3: Strata 1 + Strata 2; Calculate as (numerator 1 + numerator 2 )/(denominator 1 + denominator 2), not the average of the performance rates"
ACRAD34,abdomen,Percent of CT Abdomen-pelvis exams with contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level
ACRAD34,chest,Percent of CT Chest exams without contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level
ACRAD34,head,Percent of CT Head/brain exams without contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level
AJRR11,neckpain,"Percentage of denominator patients who showed a statistically significant improvement in comparison to initial assessment, measured by minimum clinically important difference (MCID), in neck pain."
AJRR11,backpain,"Percentage of denominator patients who showed a statistically significant improvement in comparison to initial assessment, measured by minimum clinically important difference (MCID), in back pain."
AJRR11,armpain,"Percentage of denominator patients who showed a statistically significant improvement in comparison to initial assessment, measured by minimum clinically important difference (MCID), in arm pain."
AJRR11,legpain,"Percentage of denominator patients who showed a statistically significant improvement in comparison to initial assessment, measured by minimum clinically important difference (MCID) in leg pain."
AJRR7,hip,represents total hip arthroplasty
AJRR7,knee,represents total knee arthroplasty.
AJRR9,hip,represents total hip arthroplasty
AJRR9,knee,represents total knee arthroplasty.
AQI48,surveyed,"The first performance rate, AQI48a, describes the percentage of surgical patients who receive a survey of their experience with anesthesia care."
AQI48,overall,"The second performance rate, AQI48b, describes the percentage of surgical patients who report a positive experience with anesthesia care."
AQI71,overall,"The overall measure score will be calculated as an average of the performance rates of parts A, B, C and D. (Rates 2, 3, 4 & 5)"
AQI71,testedPrior,"Percentage of patients, aged 18 years and older, with a current diagnosis of diabetes mellitus receiving anesthesia services for office-based or ambulatory surgery whose blood glucose level is tested prior to the start of anesthesia"
AQI71,insulinPrior,"Percentage of patients, aged 18 years and older, with a current diagnosis of diabetes mellitus receiving anesthesia services for office-based or ambulatory surgery who experienced a blood glucose level greater than 180 mg/dL (10.0 mmol/L) who received insulin prior to anesthesia end time"
AQI71,insulinPostoperative,"Percentage of patients, aged 18 years and older, with a current diagnosis of diabetes mellitus receiving anesthesia services for office-based or ambulatory surgery who received insulin perioperatively and who received a follow-up blood glucose level check following the administration of insulin and prior to discharge"
AQI71,glucoseEducation,"Percentage of patients, aged 18 years and older, with a current diagnosis of diabetes mellitus receiving anesthesia services for office-based or ambulatory surgery who experienced a blood glucose level greater than 180 mg/dL (10.0 mmol/L) who received education on managing their glucose in the postoperative period prior to discharge"
GIQIC23,overall,Overall percentage of procedures among average-risk patients aged 45 to 75 years receiving a screening colonoscopy with biopsy or polypectomy and pathology findings who had a follow-up interval consistent with US Multi-Society Task Force (USMSTF) recommendations for repeat colonoscopy documented in their colonoscopy report
GIQIC23,hyperPolyps&FollowUp,Percentage of complete and adequately prepped screening colonoscopies of average-risk patients aged 45 to 75 years with biopsy or polypectomy and pathology findings of only hyperplastic polyps for which a recommended follow-up interval of 10 years for repeat colonoscopy was given to the patient
GIQIC23,1-2adenoma&FollowUp,Percentage of complete and adequately prepped screening colonoscopies of average-risk patients aged 45 to 75 years with biopsy or polypectomy and pathology findings of 1-2 tubular adenoma(s) for which a recommended follow-up interval of not less than 7 years and not greater than 10 years was given to the patient
GIQIC23,3-4adenomas&FollowUp,Percentage of complete and adequately prepped screening colonoscopies of average-risk patients aged 45 to 75 years with biopsy or polypectomy and pathology findings of 3-4 tubular adenomas for which a recommended follow-up interval of not less than 3 years and not greater than 5 years was given to the patient
GIQIC23,5-10adenoma&FollowUp,Percentage of complete and adequately prepped screening colonoscopies of average-risk patients aged 45 to 75 years with biopsy or polypectomy and pathology findings of 5-10 tubular adenomas for which a recommended follow-up interval of 3 years was given to the patient
GIQIC23,neoplasm&FollowUp,"Percentage of complete and adequately prepped screening colonoscopies of average-risk patients aged 45 to 75 years with biopsy or polypectomy and pathology findings of Advanced Neoplasm (>= 10 mm, high grade dysplasia, villous component) for which a recommended follow-up interval of 3 years for repeat colonoscopy was given to the patient"
GIQIC23,serration&FollowUp,Percentage of complete and adequately prepped screening colonoscopies of average-risk patients aged 45 to 75 years with biopsy or polypectomy and pathology findings of Sessile serrated polyp >= 10 mm OR sessile serrated polyp with dysplasia OR traditional serrated adenoma who had a recommended follow-up interval of 3 years for repeat colonoscopy consistent was given to the patient
HM7,14to17,SUBMISSION CRITERIA 1: Patients aged 14-17 years of age on date of encounter
HM7,18to64,SUBMISSION CRITERIA 2: Patients aged 18-64 years and older on date of encounter
HM7,65over,SUBMISSION CRITERIA 3: Patients aged 65 years of age and older on date of encounter
HM7,overall,SUBMISSION CRITERIA 4: Patients aged 14 years of age and older on date of encounter
MBHR10,screening,"Documentation of a standardized tool to assess ADHD (i.e., ASRS checklist) and a document care of plan "
MBHR10,overall,"Patient demonstrated an ASRS score that is reduced by 25% or greater from the index score, 2-10 months after index date"
USWR32,noRestrictions,Normal arterial supply based on testing- No restrictions on type of compression
USWR32,specialConsideration,"Compression bandaging with special considerations (e.g., short stretch bandaging, warnings to the patient to remove bandages if they feel too tight, etc.)"
USWR32,notRecommended,Compression bandaging not recommended
USWR32,overall,The average of the three risk stratified buckets which will be the performance rate in the JSON XML submitted.